0 CHECKOUT

Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2015

  • ID: 3446765
  • September 2015
  • 82 pages
  • Global Markets Direct
1 of 3

Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2015

Summary

The report ‘Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2015’, provides an overview of the Allergic Rhino-Conjunctivitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes READ MORE >

Note: Product cover images may vary from those shown
2 of 3

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Allergic Rhino-Conjunctivitis Overview

Therapeutics Development

Pipeline Products for Allergic Rhino-Conjunctivitis - Overview

Allergic Rhino-Conjunctivitis - Therapeutics under Development by Companies

Allergic Rhino-Conjunctivitis - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Allergic Rhino-Conjunctivitis - Products under Development by Companies

Allergic Rhino-Conjunctivitis - Companies Involved in Therapeutics Development

ALK-Abello A/S

Allergopharma Joachim Ganzer KG

Allergy Therapeutics Plc

Bial - Portela & Ca, S.A.

BioTech Tools s.a.

Circassia Pharmaceuticals Plc

Greer Laboratories, Inc.

HAL Allergy BV

Immunomic Therapeutics, Inc.

Laboratorios LETI S.L.

Oxagen Limited

Stallergenes S.A.

Allergic Rhino-Conjunctivitis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AL-0704rP - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Allergen for Cupressus Arizonica Pollen Induced Allergic Rhino-Conjunctivitis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Allergen for Salsola Kali Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Allergovac - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ASP-4070 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

gp-ASIT - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MK-8237 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

OC-000459 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Olea Europaea Pollen Extract - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Pollinex Quattro Grass - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Ragweed Pollen Extract - Drug Profile

Product Description

Mechanism of Action

R&D Progress

rBet v1 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

rBet v1-FV - Drug Profile

Product Description

Mechanism of Action

R&D Progress

rPhleum - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Vaccine for Allergic Rhino-Conjunctivitis and House Dust Mite Allergy - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Vaccine for Asthma, Grass Pollen Allergy and Allergic Rhino-Conjunctivitis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Allergic Rhino-Conjunctivitis - Recent Pipeline Updates

Allergic Rhino-Conjunctivitis - Dormant Projects

Allergic Rhino-Conjunctivitis - Discontinued Products

Allergic Rhino-Conjunctivitis - Product Development Milestones

Featured News & Press Releases

Jun 09, 2014: ALK presents Phase III data on house dust mite SLIT-tablet at EAACI Annual Congress in Copenhagen

May 18, 2014: BioTech Tools will be present at the EAACI congress

Mar 10, 2014: GREER Investigational Sublingual Allergy Immunotherapy Liquid (SAIL) for Short Ragweed Allergies Phase III Data Published in Journal of Allergy and Clinical Immunology

Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics

Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites

Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Allergic Rhino-Conjunctivitis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Allergic Rhino-Conjunctivitis - Pipeline by ALK-Abello A/S, H2 2015

Allergic Rhino-Conjunctivitis - Pipeline by Allergopharma Joachim Ganzer KG, H2 2015

Allergic Rhino-Conjunctivitis - Pipeline by Allergy Therapeutics Plc, H2 2015

Allergic Rhino-Conjunctivitis - Pipeline by Bial - Portela & Ca, S.A., H2 2015

Allergic Rhino-Conjunctivitis - Pipeline by BioTech Tools s.a., H2 2015

Allergic Rhino-Conjunctivitis - Pipeline by Circassia Pharmaceuticals Plc, H2 2015

Allergic Rhino-Conjunctivitis - Pipeline by Greer Laboratories, Inc., H2 2015

Allergic Rhino-Conjunctivitis - Pipeline by HAL Allergy BV, H2 2015

Allergic Rhino-Conjunctivitis - Pipeline by Immunomic Therapeutics, Inc., H2 2015

Allergic Rhino-Conjunctivitis - Pipeline by Laboratorios LETI S.L., H2 2015

Allergic Rhino-Conjunctivitis - Pipeline by Oxagen Limited, H2 2015

Allergic Rhino-Conjunctivitis - Pipeline by Stallergenes S.A., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Allergic Rhino-Conjunctivitis Therapeutics - Recent Pipeline Updates, H2 2015

Allergic Rhino-Conjunctivitis - Dormant Projects, H2 2015

Allergic Rhino-Conjunctivitis - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Allergic Rhino-Conjunctivitis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Merck & Co., Inc.
  • Celgene Corporation
  • GlaxoSmithKline PLC
  • Genentech, Inc.
  • Johnson & Johnson Services, Inc.
  • ViiV Healthcare